Uncategorized
First patient enrolled in EyeGate’s phase 3 trial of EGP-437 for noninfectious anterior uveitis
The first patient has been enrolled in a confirmatory phase 3 clinical trial of EGP-437 to treat noninfectious anterior uveitis, according to a press release from EyeGate Pharmaceuticals.EGP-437 is an iontophoretically delivered formulation of dexamethasone phosphate ophthalmic solution.